Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
42 hedge funds and large institutions have $21.8M invested in Paratek Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 15 closing their positions.
3% more capital invested
Capital invested by funds: $21.2M → $21.8M (+$654K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 47 → 42 (-5)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
92% less call options, than puts
Call options by funds: $46K | Put options by funds: $554K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOM
Loeb Offshore Management
New York
|
+$301K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$200K |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$155K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$97.6K |
| 5 |
Morgan Stanley
New York
|
+$84.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$296K |
| 2 |
TPM
T2 Partners Management
New York
|
-$182K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$165K |
| 4 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$148K |
| 5 |
Millennium Management
New York
|
-$109K |
PRTK Hedge Fund Activity: Q3 2013 in Review
42 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2013, worth a combined $21.8M — up 3.1% from $21.2M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PRTK and 10 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 11 added.
The largest buyer was Loeb Offshore Management, opening a new position worth an estimated $301K. The largest seller was Northern Trust, cutting an estimated $296K.
- 42 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2013, down from 47 in Q2 2013.
- Funds reported $21.8M of Paratek Pharmaceuticals, Inc. stock for Q3 2013, up 3.1% quarter-over-quarter.
- 10 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2013 and 15 closed out, a net change of -5 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2013 was Loeb Offshore Management, an estimated $301K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2013 was Northern Trust, an estimated $296K sold.
Based on aggregated 13F filings for Q3 2013.